Hypermarcas (OTCMKTS:HYPMY) Stock Short Interest Report for September

Hypermarcas (OTCMKTS:HYPMY) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 4,266 shares, a growth of 82.1% from the September 15th total of 2,343 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 20,164 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Hypermarcas Trading Up 5.0%

OTCMKTS:HYPMY traded up $0.25 during mid-day trading on Friday, hitting $5.30. 45,763 shares of the stock traded hands, compared to its average volume of 285,876. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50. Hypermarcas has a 52 week low of $3.72 and a 52 week high of $5.77. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of 10.60 and a beta of 0.65. The firm’s 50 day moving average is $4.57 and its two-hundred day moving average is $4.40.

Hypermarcas (OTCMKTS:HYPMY) last released its earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, equities research analysts predict that Hypermarcas will post 0.51 earnings per share for the current year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.

The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.

In 2018, Hypermarcas changed its corporate name to Hypera SA, adopting the Hypera Pharma identity.